Business
Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution
TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate credit rating to Investment Grade BBB-, with a stable outlook, from BB+. “This strong endorsement, our third upgrade from Fitch in less than two years, underscores Teva’s transformation journey and execution of its Pivot to Growth strategy, as well as shows confidence in our increasing financial flexibi
About this update from Teva Pharmaceutical Industries Limited
[{"type":"image","alt":"Teva Pharmaceutical Industries Ltd","displaySize":"","headline":null,"caption":"Teva Pharmaceutical Industries Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/bfbffad044ba3112cbe08e7be13bb2e7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RVm0LbdD5btgTSMRlhCNHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MQ--/https://media.zenfs.com/en/globenewswire.com/bfbffad044ba3112cbe08e7be13bb2e7","width":300,"height":108},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/RVm0LbdD5btgTSMRlhCNHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MQ--/https://media.zenfs.com/en/globenewswire.com/bfbffad044ba3112cbe08e7be13bb2e7","width":300,"height":108}},"lazy":false},{"type":"text","content":"TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate credit rating to Investment Grade BBB-, with a stable outlook, from BB+.","length":272,"tagName":"p"},{"type":"text","content":"“This strong endorsement, our third upgrade from Fitch in less than two years, underscores Teva’s transformation journey and execution of its Pivot to Growth strategy, as well as shows confidence in our increasing financial flexibility” said Eli Kalif, Teva’s Chief Financial Officer.","length":284,"tagName":"p"},{"type":"text","content":"Fitch has also upgraded its ratings on Teva's senior unsecured debt and credit facilities to BBB- from BB+.","length":111,"tagName":"p"},{"type":"text","content":"Fitch’s report highlights Teva’s sustained progress in strengthening financial flexibility and advancing its transition toward a higher-margin innovative and biosimilar portfolio. Fitch expects continued growth in innovative revenues, led by AUSTEDO® and AJOVY®; as well as contributions from recently launched products such as UZEDY® and upcoming launches, including olanzapine LAI, subject to regulatory approval. Fitch also expects Teva’s efficiency programs and portfolio shift to support its operating margin improvement and continued strong cash generation. Fitch further noted Teva’s ongoing balance sheet strengthening, supported by sustained cash flow generation, enhancing financial flexibility.","length":710,"tagName":"p"},{"type":"text","co...